Rhenovia Pharma opens first U.S. office
Rhenovia Pharma, a biotechnology company specializing in biosimulation to aid discovery of treatments for brain diseases, has formed its first international subsidiary, Rhenovia Inc. The new operation will be based in Cambridge, Mass.
Rhenovia Inc. will provide biosimulation technology for healthcare, focusing on accelerating the search for new treatments of diseases of the central and peripheral nervous system via its service partnership offers in the form of studies. It uses proprietary tools such as high throughput search for synergistic drug combinations, numerical pharmacological compound profiling, anticipation of safety/toxicity and drug-drug interaction risks, and alliances for the implementation of its biosimulation approach in healthcare.
Rhenovia Inc. will provide specific, customized offers for U.S. pharma and biotech companies aimed at increasing their R&D productivity and reducing costs, time-to-market and risks of failures. It also aims to help U.S. academic research groups and scientists increase the understanding of basic mechanisms underlying diseases while contributing more efficiently to healthcare and patients' well-being.
Rhenovia will also look to expand its emerging drug candidate pipeline, as well as offer investment opportunities.
"It's the right time to intensify our commercial activity," said Dr. Serge Bischoff, president and CEO, Rhenovia Pharma. "It's also time to disseminate worldwide the huge potential of Rhenovia's breakthrough technology of modeling and simulating neuronal transmission under normal and pathological conditions in the brain, the eye, the spinal cord and muscular junction."
While biosimulation is routinely used in almost all non-CNS therapeutic fields, such as cardiovascular or infectious diseases, oncology, asthma or HIV, it is still an emerging technology in the field of mental, neurological, neurodegenerative and neurodevelopmental diseases.
Rhenovia has partners from such diverse areas as the nutrition industry, for the prevention of diseases by optimizing food; defense ministries and organizations to protect populations against war/terrorism neurotoxic agents; chemical and agrochemical industries and regulatory organs and stakeholders in the field of cleantech and eco-toxicity, which assess the neurological impacts of a great variety of active compounds and molecules.